Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574882 | 0.91 | GRIN2B (0.53) | RAB9ATHRBUBE2MDCUN1D1GRIN2B | |
| SCHEMBL1574645 | 0.91 | NPC1 (0.47) | NPC1RAB9ATHRBTP53UBE2M | |
| SCHEMBL1574520 | 0.90 | GRIN2B (0.51) | NPC1RAB9ATP53UBE2MDCUN1D1 | |
| SCHEMBL1575336 | 0.89 | HPGD (0.47) | NPC1RAB9ATP53GRIN2BFAAH | |
| SCHEMBL1575217 | 0.88 | NPSR1 (0.46) | NPC1RAB9ATP53UBE2MDCUN1D1 | |
| SCHEMBL1575761 | 0.88 | UBE2M (0.43) | NPC1RAB9AUBE2MDCUN1D1GRIN2B | |
| SCHEMBL1574584 | 0.87 | NPC1 (0.53) | NPC1RAB9ATP53UBE2MDCUN1D1 | |
| SCHEMBL1574527 | 0.86 | GRIN2B (0.49) | UBE2MDCUN1D1GRIN2BFAAHNAMPT | |
| SCHEMBL1574541 | 0.84 | UBE2M (0.45) | NPC1RAB9AUBE2MDCUN1D1FAAH | |
| SCHEMBL1574710 | 0.84 | GRIN2B (0.52) | NPC1RAB9AGRIN2BFAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-B1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | NPC1 413/4885RAB9A 898/4885THRB 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.